[1] Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther. 6(3):945-56 (2007).
[2] Kotz, J, et al. PARP target practice.SciBX. 5(13) (2012).
[3] Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene.31(2):251-264 (2012).
[4]Daniel RA, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res. 15(4):1241-9 (2009).